Latest EMA401 Stories
MELBOURNE, Australia and STAMFORD, Connecticut, June 3, 2014 /PRNewswire/ -- Spinifex Pharmaceuticals, a pain drug development company, today announces that it has appointed
MELBOURNE, Australia, May 27, 2014 /PRNewswire/ -- Expanded SAB will oversee development of EMA401, Company's lead program for
MELBOURNE, Australia, February 5, 2014 /PRNewswire/ -- - Phase 2 trial met its primary endpoint, reduced pain in postherpetic neuralgia (PHN) versus
- A serpent whose bite was fabled to produce intense thirst.